
COMPASS Pathways (CMPS) Stock Forecast & Price Target
COMPASS Pathways (CMPS) Analyst Ratings
Bulls say
Compass Pathways is a biotechnology company that is paving the way for innovation in mental health treatment. With a strong focus on developing drugs with novel mechanisms of action for high unmet need psychiatric disorders, the company's flagship product, COMP360, has shown great promise in treating treatment-resistant depression and PTSD. The company's strong financial position, with cash runway into 2028, and a low-risk regulatory path, sets it up for a successful launch and growth potential.
Bears say
Compass Pathways is heavily reliant on the success of its proprietary synthetic psilocybin formulation, COMP360, and the positive results from its late-stage clinical trials for the treatment of mental health conditions. However, the company's management has been criticized for their framing of outcomes and the lack of meaningful support during therapy sessions, raising doubts about the effectiveness of their treatment. With a limited product portfolio and high stakes on clinical trials, any setbacks or negative outcomes could significantly impact the company's long-term success and profitability.
This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.
COMPASS Pathways (CMPS) Analyst Forecast & Price Prediction
Start investing in COMPASS Pathways (CMPS)
Order type
Buy in
Order amount
Est. shares
0 shares